Pulmonary Edema Therapeutics

Pulmonary Edema Therapeutics

Global Pulmonary Edema Therapeutics Market to Reach US$2.4 Billion by 2030

The global market for Pulmonary Edema Therapeutics estimated at US$2.1 Billion in the year 2023, is expected to reach US$2.4 Billion by 2030, growing at a CAGR of 1.7% over the analysis period 2023-2030. Cardiogenic Pulmonary Edema Therapeutics, one of the segments analyzed in the report, is expected to record a 1.9% CAGR and reach US$1.5 Billion by the end of the analysis period. Growth in the Non-Cardiogenic Pulmonary Edema Therapeutics segment is estimated at 1.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$584.1 Million While China is Forecast to Grow at 3.7% CAGR

The Pulmonary Edema Therapeutics market in the U.S. is estimated at US$584.1 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$463.0 Million by the year 2030 trailing a CAGR of 3.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.3% and 1.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.7% CAGR.

Global Pulmonary Edema Therapeutics Market - Key Drivers and Trends Summarized

Pulmonary edema is a serious medical condition characterized by the accumulation of fluid in the lungs` air sacs, leading to impaired gas exchange and difficulty breathing. This condition can result from various causes, including congestive heart failure, acute respiratory distress syndrome (ARDS), high altitude, and exposure to certain toxins or medications. The primary goal of pulmonary edema treatment is to remove the excess fluid, improve oxygenation, and address the underlying cause. Therapeutic approaches typically involve a combination of pharmacological and non-pharmacological interventions, tailored to the patient`s specific condition and severity.

Pharmacological treatments for pulmonary edema primarily include diuretics, such as furosemide, which help to reduce fluid accumulation by promoting its excretion through the kidneys. Vasodilators like nitroglycerin are also used to decrease the pressure in the blood vessels, reducing the workload on the heart and helping to alleviate fluid buildup in the lungs. In cases where pulmonary edema is caused by heart failure, medications like ACE inhibitors or beta-blockers may be prescribed to improve heart function. Non-pharmacological treatments can include oxygen therapy to improve oxygen levels in the blood and mechanical ventilation in severe cases to support breathing. Additionally, lifestyle modifications, such as reducing salt intake and managing fluid balance, are essential components of long-term management for patients with chronic conditions that predispose them to pulmonary edema.

The growth in the pulmonary edema therapeutics market is driven by several factors. Firstly, the increasing prevalence of cardiovascular diseases, which are a major cause of pulmonary edema, has significantly boosted the demand for effective treatments. Secondly, advancements in medical research have led to the development of new and improved pharmacological therapies that offer better efficacy and safety profiles. The aging global population, which is more prone to heart-related conditions and respiratory issues, has further fueled market growth. Additionally, the expansion of healthcare infrastructure and access to advanced medical care in emerging markets has increased the availability of pulmonary edema treatments. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the discovery and commercialization of innovative therapies. Lastly, heightened awareness and early diagnosis of pulmonary edema among healthcare professionals and patients have driven the demand for timely and effective therapeutic interventions, solidifying the market`s growth trajectory.

Select Competitors (Total 86 Featured) -

• Bayer AG
• Citius Pharmaceuticals, Inc.
• Edesa Biotech
• Exponential Biotherapies
• Genentech, Inc.
• Lupin Ltd.
• Pantherna Therapeutics GmbH
• Pfizer Inc.
• Qx Therapeutics, Inc.
• Sun Pharmaceutical Industries Ltd.;

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.